Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 8Head & Neck 7Sarcoma 3Thoracic 1Other hematologic neoplasm 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 879Leukemia, Lymphocytic, Chronic, B-Cell 560Leukemia 426Hematologic Neoplasms 332Precursor Cell Lymphoblastic Leukemia-Lymphoma 331Myelodysplastic Syndromes 302Leukemia, Myelogenous, Chronic, BCR-ABL Positive 244Lymphoma, Non-Hodgkin 224Recurrence 222Lymphoma 196Neoplasms 195Multiple Myeloma 129Lymphoma, Mantle-Cell 119Lymphoma, Large B-Cell, Diffuse 114Lymphoma, Follicular 114Leukemia, Myelomonocytic, Chronic 89Lymphoma, B-Cell 88Lymphoma, B-Cell, Marginal Zone 85Leukemia, B-Cell 79Burkitt Lymphoma 64Leukemia, Myeloid, Chronic-Phase 57Waldenstrom Macroglobulinemia 56Leukemia, Myeloid 53Hodgkin Disease 47Hematologic Diseases 47Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 45Myeloproliferative Disorders 40Primary Myelofibrosis 39Bronchiolitis Obliterans Syndrome 35Anemia, Refractory, with Excess of Blasts 32

Interventions

brincidofovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Epstein-Barr Virus Infections × Other hematologic neoplasm × Clear all
NCT06761677 2026-02-05

A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma

SymBio Pharmaceuticals

Phase 1/2 Suspended
43 enrolled
LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, Recurrence, Leukemia-Lymphoma, Adult T-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Epstein-Barr Virus Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡